Grothey A - Search Results

1

KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice.

Blanke CD, Goldberg RM, Grothey A, Mooney M, Roach N, Saltz LB, Welch JJ, Wood WA, Meropol NJ; NCI GI Steering Committee Colon Cancer Task Force. Blanke CD, et al. Among authors: grothey a. Oncologist. 2011;16(8):1061-8. doi: 10.1634/theoncologist.2011-0011. Epub 2011 Jul 7. Oncologist. 2011. PMID: 21737577 Free PMC article.

2

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.

Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Grothey A, et al. J Clin Oncol. 2004 Apr 1;22(7):1209-14. doi: 10.1200/JCO.2004.11.037. J Clin Oncol. 2004. PMID: 15051767

3

A review of oxaliplatin and its clinical use in colorectal cancer.

Grothey A, Goldberg RM. Grothey A, et al. Expert Opin Pharmacother. 2004 Oct;5(10):2159-70. doi: 10.1517/14656566.5.10.2159. Expert Opin Pharmacother. 2004. PMID: 15461551 Review.

4

Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.

Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH. Folprecht G, et al. Among authors: grothey a. Ann Oncol. 2005 Aug;16(8):1311-9. doi: 10.1093/annonc/mdi246. Epub 2005 May 3. Ann Oncol. 2005. PMID: 15870084 Free article.

5

FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer.

Grothey A, Sargent DJ. Grothey A, et al. J Clin Oncol. 2005 May 20;23(15):3311-3. doi: 10.1200/JCO.2005.11.691. J Clin Oncol. 2005. PMID: 15908645 No abstract available.

6

Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab.

Ellis LM, Curley SA, Grothey A. Ellis LM, et al. Among authors: grothey a. J Clin Oncol. 2005 Aug 1;23(22):4853-5. doi: 10.1200/JCO.2005.23.754. J Clin Oncol. 2005. PMID: 16051943 No abstract available.

7

Clinical trial designs for prospective validation of biomarkers.

Mandrekar SJ, Grothey A, Goetz MP, Sargent DJ. Mandrekar SJ, et al. Among authors: grothey a. Am J Pharmacogenomics. 2005;5(5):317-25. doi: 10.2165/00129785-200505050-00004. Am J Pharmacogenomics. 2005. PMID: 16196501

8

N0147: a randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer.

Alberts SR, Sinicrope FA, Grothey A. Alberts SR, et al. Among authors: grothey a. Clin Colorectal Cancer. 2005 Sep;5(3):211-3. doi: 10.3816/ccc.2005.n.033. Clin Colorectal Cancer. 2005. PMID: 16197625 Clinical Trial. No abstract available.

9

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A. Sargent DJ, et al. Among authors: grothey a. J Clin Oncol. 2005 Dec 1;23(34):8664-70. doi: 10.1200/JCO.2005.01.6071. Epub 2005 Oct 31. J Clin Oncol. 2005. PMID: 16260700

10

Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line.

Grothey A, Sargent D. Grothey A, et al. J Clin Oncol. 2005 Dec 20;23(36):9441-2. doi: 10.1200/JCO.2005.04.4792. J Clin Oncol. 2005. PMID: 16361649 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

382 results

Search Page

Filters